Overview

Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

Status:
Active, not recruiting
Trial end date:
2031-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if a three method risk adapted design using induction chemotherapy, transoral surgery and radiation chemotherapy will lessen toxic effects and make treatment of squamous cell carcinoma of the head and neck (SCCHN) better.
Phase:
Phase 2
Details
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Collaborator:
GlaxoSmithKline
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Cisplatin
Lapatinib
Paclitaxel